The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

The purpose of this clinical trial (called the FLOTILLA study) is to give continued access to the study medicines, as well as safety follow-up, for participants in prior clinical trials of encorafenib and/or binimetinib. All participants who took part in earlier encorafenib and/or binimetinib studies may participate in the FLOTILLA study if they are still benefiting from the use of the study medicines. This will be determined by the study doctor. People may not participate in the FLOTILLA study if they were not enrolled in a prior study of encorafenib or binimetinib. Participants who had enrolled but had stopped receiving the study treatment in a prior study cannot be enrolled in this study. Participants in the FLOTILLA study will receive study treatment at the same dose and frequency as in their prior study, for up to about 5 years.

Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT05203172.

Trial PhasePhase IV

Trial Typetreatment

Lead OrganizationPfizer Inc

• Primary IDC4221026
• Secondary IDsNCI-2022-05524, 2021-004395-34, 2023, 2023-509408-13-00, FLOTILLA
• ClinicalTrials.gov IDNCT05203172